Tag: ALL

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Read more
onclive7

Risk-Adapted CAR T Dosing Maintains Efficacy, Improves Safety in Pediatric Relap...

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden.

Visit website
Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Read more
Immunotherapy Web Featured Images 123

Experimental safety switch reduces severity of CAR-T immunotherapy-related side ...

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

Visit website
Touch Oncology

Optimizing care with CAR T-cell therapy now and in the future for patients with ...

  Mar 03 2021 Tagged CAR-T, LBCL, ALL, NHL

Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.

Visit website
Immunotherapy Web Featured Images 100

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.

Read more
Immunotherapy Web Featured Images 101

AEMPS authorises Hospital Clínic's CAR-T ARI-0001 for patients with acute lympho...

The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved CAR-T ARI-0001, developed by Hospital Clínic, as an advanced therapy drug of non-industrial production for its use in patients over 25 years of age with lymphoblastic leukaemia that is resistant to conventional treatments. It is the first CAR-T developed entirely in Europe to be approved by a regulatory agency.

Visit website
Immunotherapy Web Featured Images 100

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.

Read more
vjhemonic6

UCART22 for R/R B-cell ALL

Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, presents the preliminary results of Balli-01 (NCT04150497), a Phase I study trialling the chimeric antigen receptor (CAR) T-cell therapy, UCART22, in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL).

Visit website
Immunotherapy Web Featured Images 62

Interim data of D-ALBA study: blinatumomab and TKI therapy as consolidation and ...

Prof Geyer speaks to ecancer about an ongoing phase II study which has been presented at this year’s ASH virtual conference regarding blinatumomab and concurrent oral tyrosine kinase inhibitor therapy as consolidation and maintenance therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia following chemotherapy-sparing induction.

Visit website